Sabatolimab
Sabatolimab
Sabatolimab is a monoclonal antibody that targets the TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) receptor, which is involved in the regulation of immune responses. It is being investigated for its potential use in the treatment of various hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Mechanism of Action[edit | edit source]
Sabatolimab functions by binding to the TIM-3 receptor, which is expressed on immune cells such as T-cells and myeloid cells. TIM-3 is a checkpoint receptor that, when activated, can inhibit immune responses. By blocking TIM-3, sabatolimab aims to enhance the immune system's ability to attack cancer cells. This mechanism is similar to other immune checkpoint inhibitors, such as those targeting PD-1 or CTLA-4, but TIM-3 offers a distinct pathway for modulating immune activity.
Clinical Development[edit | edit source]
Sabatolimab is currently undergoing clinical trials to evaluate its safety and efficacy in patients with hematologic cancers. Early-phase studies have shown promising results, with some patients experiencing reductions in disease burden. Ongoing trials are assessing its use both as a monotherapy and in combination with other treatments, such as hypomethylating agents.
Potential Indications[edit | edit source]
Sabatolimab is primarily being studied for its application in:
- Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells.
- Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow characterized by an overproduction of immature white blood cells.
Side Effects[edit | edit source]
As with other immune checkpoint inhibitors, sabatolimab may cause immune-related adverse events. These can include inflammation of healthy tissues, leading to conditions such as colitis, hepatitis, or pneumonitis. The safety profile of sabatolimab is still being characterized through ongoing clinical trials.
Research and Development[edit | edit source]
Sabatolimab is being developed by Novartis, a global healthcare company. The drug is part of a broader effort to develop novel immunotherapies that can improve outcomes for patients with difficult-to-treat cancers.
Also see[edit | edit source]
- Monoclonal Antibody Therapy
- Immune Checkpoint Inhibitors
- Cancer Immunotherapy
- Hematologic Malignancies
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
